1. We are currently developing a kit for the detection of circulating tumor cells from blood samples.​ 

Circulating Tumor Cell Detection Kit 

Cancer is the second leading cause of death worldwide next to cardiovascular diseases. Detecting cancer at an advanced stage severely limits treatment options and results in poor prognosis. Therefore, detecting cancer at an early stage will improve patient outcomes. The current gold standard for cancer diagnosis is histopathology which involves an invasive biopsy from solid tumor tissue but usually, this test is ordered only when there are symptoms. In addition, multi-parametric MRI and PET-CT can only detect primary tumors and metastases that are well-established. Circulating tumor cells in blood might be the first indicator of the early steps of cancer metastasis, as when the tumor grows even a few millimetres they release cancer cells in circulation to promote metastasis. FDA has approved CELLSEARCH for the Detection of CTCs and predicting prognosis and treatment efficacy of metastatic prostate cancer, breast cancer and colorectal cancer. We have utilized novel markers that can be efficient in identifying the CTCs. This kit can be used by hospitals and Diagnostic centers with minimal facilities (specialized instruments required) and minimally trained personnel.​​